Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin

References

• LiuCBayerACosgroveSEClinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and childrenClin Infect Dis201152e18e5521208910
   PubMed Web of Science ®Google Scholar
• Zyvox® [package insert]New York, NYPharmacia and Upjohn Company2010
   Google Scholar
• BartlettJImpact of new oral antibiotics on the treatment of infectious diseasesInfect Dis Clin Pract19932405413
   Web of Science ®Google Scholar
• CunhaBAOral antibiotic therapy of serious systemic infectionsMed Clin North Am2006901197122217116444
   PubMed Web of Science ®Google Scholar
• BounthavongMHsuDIEfficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysisCurr Med Res Opin20102640742120001574
   PubMed Web of Science ®Google Scholar
• DoddsTJHawkeCILinezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis)ANZ J Surg20097962963519895519
   PubMed Web of Science ®Google Scholar
• ItaniKMDrydenMSBhattacharyyaHKunkelMJBaruchAMWeigeltJAEfficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureusAm J Surg201019980481620227056
   PubMed Web of Science ®Google Scholar
• LogmanJFStephensJHeegBComparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infectionsCurr Med Res Opin2010261565157820429820
   PubMed Web of Science ®Google Scholar
• SharpeJNShivelyEHPolkHCJrClinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureusAm J Surg200518942542815820454
   PubMed Web of Science ®Google Scholar
• WeigeltJItaniKStevensDLauWDrydenMKnirschCLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother2005492260226615917519
   PubMed Web of Science ®Google Scholar
• ItaniKMWeigeltJLiJZDuttaguptaSLinezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)Int J Antimicrob Agents20052644244816289514
   PubMed Web of Science ®Google Scholar
• McCollumMSorensenSVLiuLZA comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patientsClin Ther20072946947717577468
   PubMed Web of Science ®Google Scholar
• McKinnonPSSorensenSVLiuLZItaniKMImpact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infectionsAnn Pharmacother2006401017102316720705
   PubMed Web of Science ®Google Scholar
• CaffreyARQuilliamBJLaPlanteKLComparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother2010544394440020660681
   PubMed Web of Science ®Google Scholar
• LiJZWillkeRJRittenhouseBERybakMJEffect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant Staphylococci: results from a randomized clinical trialSurg Infect (Larchmt)20034577012744768
   PubMedGoogle Scholar
• BarrettMWilsonEWhalenD2007 HCUP Nationwide Inpatient Sample (NIS) comparison reportHCUP Methods Series report # 2010–2003US Agency for Healthcare Research and Quality2010
   Google Scholar
• MoetGJJonesRNBiedenbachDJStilwellMGFritscheTRContemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004)Diagn Microbiol Infect Dis20075771317059876
   PubMed Web of Science ®Google Scholar
• NicolauDPContaining costs and containing bugs: are they mutually exclusive?J Manag Care Pharm200915S12S1719236136
   PubMed Web of Science ®Google Scholar
• ShahNPReddyPPaladinoJAMcKinnonPSKlepserMEPashosCLDirect medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic modelCurr Med Res Opin20042077979015200734
   PubMed Web of Science ®Google Scholar
• BounthavongMHsuDIOkamotoMPCost-effectiveness analysis of linezolid vs vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic modelInt J Clin Pract20096337638619222624
   PubMed Web of Science ®Google Scholar
• De CockESorensenSLevratFCost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in FranceMed Mal Infect20093933034019304423
   PubMed Web of Science ®Google Scholar
• PatanwalaAEErstadBLNixDECost-effectiveness of linezolid and vancomycin in the treatment of surgical site infectionsCurr Med Res Opin20072318519317257479
   PubMed Web of Science ®Google Scholar
• SchurmannDSorensenSVDe CockEDuttaguptaSReschACost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in GermanyEur J Health Econ200910657918437437
   PubMed Web of Science ®Google Scholar
• BounthavongMZargarzadehAHsuDIVannessDJCost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesisValue Health20111463163921839399
   PubMed Web of Science ®Google Scholar
• DavisSLMcKinnonPSHallLMDaptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomesPharmacotherapy200727121611161818041881
   PubMed Web of Science ®Google Scholar
• WeigeltJKaafaraniHMItaniKMSwansonRNLinezolid eradicates MRSA better than vancomycin from surgical-site infectionsAm J Surg200418876076615619496
   PubMed Web of Science ®Google Scholar
• EdelsbergJBergerAWeberDJMallickRKuznikAOsterGClinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infectionsInfect Control Hosp Epidemiol20082916016918179372
   PubMed Web of Science ®Google Scholar
• ItaniKMFWeigeltJStevensMSEfficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus (MRSA)Presentation at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)Reinach, SwitzerlandApril 2008
   Google Scholar
• ItaniKSorensenSStokesMShelbayaAMcKinnonPSA regional comparison of resource utilization in patients with methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infections (cSSTI) treated with linezolid vs vancomycin49th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 12–15, 2009San Francisco, CA
   Google Scholar
• MoureauNPooleSMurdockMAGraySMSembaCPCentral venous catheters in home infusion care: outcomes analysis in 50,470 patientsJ Vasc Interv Radiol2002131009101612397122
   PubMed Web of Science ®Google Scholar
• TiceABonstellRMarshPKCravenPCMcEniryDWHardingSPeripherally inserted central venous catheters for outpatient intravenous antibiotic therapyInfect Dis Clin Pract19932186190
   Web of Science ®Google Scholar
• TiceADHoaglundPANoletBMcKinnonPSMozaffariECost perspectives for outpatient intravenous antimicrobial therapyPharmacotherapy20022263S70S11837549
   PubMed Web of Science ®Google Scholar
• TiceADTurpinRSHoeyCTLipskyBAWuJAbramsonMAComparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infectionsAm J Health Syst Pharm2007641080108617494908
   PubMed Web of Science ®Google Scholar
• First Data Bank, IncAnaly$ource OnlineFirst DataBank, IncSouth San Francisco, CA492011
   Google Scholar
• CandrilliSMauskopfJHow much does a hospital day cost?Value Health2006A56
   Google Scholar
• IngenixNational Fee AnalyzerEden Prairie, MNIngenix2011
   Google Scholar
• Consumer Price IndexMedical Component [webpage on the Internet]Washington, DCUS Bureau of Labor Statistics2011 Available from: http://www.bls.gov/CPIAccessed April 2011
   Google Scholar
• ChenSCBayoumiAMSoonSLA catalog of dermatology utilities: a measure of the burden of skin diseasesJ Investig Dermatol Symp Proc20049160168
   PubMedGoogle Scholar
• ErnstEJErnstMEHoehnsJDBergusGRWomen’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatmentHealth Qual Life Outcomes200534516048650
   PubMedGoogle Scholar
• Ragnarson TennvallGApelqvistJHealth-related quality of life in patients with diabetes mellitus and foot ulcersJ Diabetes Complications20001423524111113684
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid ServicesNational Health Expenditure Web Tables Available from: http://www.cms.gov/NationalHealthExpendData/downloads/tables.pdfAccessed March 29, 2011
   Google Scholar
• MenzinJMartonJPMeyersJLCarsonRTRothermelCDFriedmanMInpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureusAm J Infect Control201038444919762120
   PubMed Web of Science ®Google Scholar
• TiceADRehmSJDalovisioJRPractice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelinesClin Infect Dis2004381651167215227610
   PubMed Web of Science ®Google Scholar
• MartonJPJackelJLCarsonRTRothermelCDFriedmanMMenzinJCosts of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claimsCurr Med Res Opin2008242821282818759996
   PubMed Web of Science ®Google Scholar
• McKinnonPSCarterCTGirasePGLiuLZCarmeliYThe economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspectiveManag Care Interface200720233417310650
   PubMedGoogle Scholar
• TiceAHandbook of Outpatient Parenteral Antimicrobial TherapyTarrytown, NYCRG Publishing2006
   Google Scholar
• GilchristMFranklinBDPatelJPAn outpatient parenteral antibiotic therapy (OPAT) map to identify risks associated with an OPAT serviceJ Antimicrob Chemother20086217718318408239
   PubMed Web of Science ®Google Scholar
• StephensJGaoXVerheggenBShelbayaAHaiderSModeling the inpatient and outpatient costs of methicillin-resistant Staphyloccocus aureus (MRSA) complicated skin and soft tissue infections (cSSTI): a comparison of linezolid, vancomycin, daptomycin, and tigecyclinePoster presentation at the 14th Annual International Society for Pharmacoeconomics and Outcomes Research International MeetingMay 18–20, 2009Orlando, FL, USA
   Google Scholar
• PaladinoJAPoretzDOutpatient parenteral antimicrobial therapy todayClin Infect Dis201051Suppl 2S198S20820731577
   PubMed Web of Science ®Google Scholar